- Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies
- The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers
- Odyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts and allow interested investors to access information regarding the company
- The website redesign follows on the company’s name change earlier this year to similarly improve the expression of its brand identity
Medical technology product developer Odyssey Health (OTC: ODYY) is advancing testing for a proprietary drug and device combination designed to deliver a novel solution for people experiencing a concussive brain injury, and the company recently introduced a redesigned website to help it better communicate its progress.
Odyssey Health has completed preclinical animal testing on its fully synthetic neurosteroid known currently as PRV-002 and is now beginning work with human clinical volunteers. In the animal testing, PRV-002 demonstrated the ability to alleviate symptoms related to concussions such as memory impairment, anxiety and motor/sensory difficulties.
The redesign of the company website follows on Odyssey’s name change earlier this year to emphasize Odyssey’s brand focus on the health therapy industry and its mission to “create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions,” including PRV-002 and products to remove a throat obstruction in a choking person, to establish a standard of early detection for heart disease, and to treat the neuro-degenerative Niemann-Pick disease.
“The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” CEO Michael Redmond stated Aug. 4 (https://ibn.fm/ATWbK).
The website’s address is www.OdysseyHealthInc.com. In addition, the company has updated its corporate presentation to better express the need for a concussive brain injury treatment as well as Odyssey’s efforts to lead the way. The new presentation can be found at https://ibn.fm/TooCZ.
The federal government’s Centers for Disease Control and Prevention (“CDC”) estimates that about 1.5 million people in the United States experience traumatic brain injuries (“TBIs”) each year (https://ibn.fm/Wb08R). The agency’s most recent data indicates that of these TBIs, about 223,135 were serious enough in 2019 to lead to hospitalizations and 64,362 resulted in death — effectively 611-plus TBI-related hospitalizations per day and 176 TBI-related deaths per day (https://ibn.fm/5ih3M).
The CDC reports that a large number of TBI deaths result from suicides, but the incidence of TBI-related injuries in child athletes, in particular, has drawn national attention to concerns about the long-term effects of head injuries and efforts to prevent or respond to them.
Professional athletes, military personnel and elderly fall victims have also been recognized as a large segment of society that could benefit from effective treatment of concussion head injuries.
Currently, the standard of care for concussions is rest, pain-relief medicine and anti-depressants. Such TBIs are generally initially reported as mild injuries (“MTBIs”) because of their minimal degree of impairment for normal activities, but the CDC’s reports note that long-term effects such as memory impairment have resulted in an estimated 5.3 million Americans living with a permanent TBI-related disability.
Repeat concussions can lead to early dementia and a condition known as Chronic Traumatic Encephalopathy (“CTE”), but at the time no drug treatment for such injuries has been approved by the U.S. Food and Drug Administration (“FDA”).
Odyssey Health’s product is an intranasal device that delivers the proprietary neurosteroid into the upper nasal cavity (but not into the esophagus or lungs), where it can be taken up into the brain, across the blood-brain barrier, to minimize the results of the injury.
The company intends to build on its flagship product with eventual therapies for other brain injury and neuropsychiatric disorders ranging from serious depression to amyotrophic lateral sclerosis (known as ALS, or Lou Gehrig’s disease).
In addition to its website, Odyssey provides updates on its activities through social media channels, such as Twitter (https://twitter.com/OdysseyHealth1), Facebook (https://www.facebook.com/odysseyhealthinc) and LinkedIn (www.linkedin.com/company/odysseyhealthinc/). YouTube: (https://www.youtube.com/channel/UCsS–v0od_fYIBu2tvqmj9Q )
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.